Back to search

Article

Anti-CD38 therapy impairs SARS-CoV-2 vaccine response in multiple myeloma patients

2021-08-09

Abstract excerpt

Multiple myeloma (MM) patients are at risk of fatal outcome after SARS-CoV-2 infection. Preliminary data suggest that MM patients have an impaired response to vaccination. This prospective study analyzed the humoral and cellular immune responses to two doses of BNT162b2 in 72 MM patients, including 48 receiving anti-CD38 immunotherapy. Results evidenced that MM patients display lower levels of SARS-CoV-2 specific...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
be099732-10fd-564e-8625-9da615caba16
DOI
10.1101/2021.08.08.21261769
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Anti-CD38 therapy impairs SARS-CoV-2 vaccine response in multiple myeloma patientsDOI 10.1101/2021.08.08.21261769
Anti-CD38 therapy impairs SARS-CoV-2 vaccine response against alpha and delta variants in patients with multiple myelomaSemantic proximity
Cellular Mechanisms Associated with Sub-Optimal Immune Responses to SARS-CoV-2 Bivalent Booster Vaccination in Patients with Multiple MyelomaSemantic proximity
Fatal breakthrough infection after anti-BCMA CAR-T therapy highlights suboptimal immune response to SARS-CoV-2 vaccination in myeloma patientsSemantic proximity
Impact of Omicron variant on the response to SARS-CoV-2 mRNA Vaccination in multiple myelomaSemantic proximity
Immunogenicity of BNT162b2 vaccine Against the Alpha and Delta Variants in Immunocompromised PatientsSemantic proximity
Targeting Attenuated Interferon-α to Myeloma Cells with a CD38 Antibody Induces Potent Tumor Regression with Reduced Off-Target Activity.Semantic proximity
Covid-19 vaccination in patients with multiple myeloma: Focus on immune response.Semantic proximity
Resistance Mechanisms towards CD38−Directed Antibody Therapy in Multiple MyelomaSemantic proximity
Targeting CD38 with Daratumumab Monotherapy in Multiple MyelomaSemantic proximity
Impaired Humoral Immunity to SARS-CoV-2 Vaccination in Non-Hodgkin Lymphoma and CLL PatientsSemantic proximity
Single dose of BNT162b2 mRNA vaccine against SARS-CoV-2 induces high frequency of neutralising antibody and polyfunctional T-cell responses in patients with myeloproliferative neoplasmsSemantic proximity
Potential role of daratumumab in the treatment of multiple myelomaSemantic proximity
Select a neighboring publication to make it the new centre.